Compare Expedia Group Inc (EXPE) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Expedia Group Inc trades at $274.22 (market cap $32.42B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Expedia Group Inc is far larger — about 2.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Expedia Group Inc pays a 0.71% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| EXPE | HALO | |
|---|---|---|
Market Cap | $32.42B | $12.58B |
Volume | 1,940,671 | 2,179,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $115.22 |
52-Week Low | $188.51 | $61.63 |
Typical Hold Time | 47 Days | 1 Days |
Enterprise Value | $30.98B | $14.49B |
Dividend Yield | 0.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $274.22, up 5.93% over the past 24 hours, reflecting strong momentum after three consecutive quarterly earnings beats. The stock shows a bullish technical signal with key resistance at $275 and support at $264. Fundamentally, the company reported $14.73B in 2025 revenue with a net income margin of 12.97%, while recent news highlights AI-driven competitive pressures and strategic partnerships.
The outlook for EXPE is cautiously optimistic, with a consensus price target of $335.06 implying 22% upside. Key opportunities include robust travel demand and improving profitability, but risks involve AI disruption from Meta's Muse agent and heightened competition. Analyst sentiment is mixed, with 47% buy ratings versus 50% hold, signaling balanced but uncertain near-term prospects.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
